What are the differential diagnoses for a 1.5‑month history of progressive ascending weakness that began in the lower limbs and spread to the upper limbs, with mild sensory loss, absent plantar responses, normal spinal and brain MRI, and a recent diagnosis of pulmonary tuberculosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Differential Diagnosis for Progressive Ascending Weakness with Recent Pulmonary Tuberculosis

The primary diagnosis to consider is Guillain-Barré syndrome (GBS), specifically the acute motor axonal neuropathy (AMAN) or acute motor sensory axonal neuropathy (AMSAN) subtype, given the ascending weakness pattern, absent plantar responses, and normal neuroimaging. 1

Most Likely Diagnosis: Guillain-Barré Syndrome

GBS should be strongly considered in this patient with rapidly progressive bilateral ascending weakness starting in the lower limbs, mild sensory loss, and absent reflexes (indicated by absent plantar responses). 1 The 1.5-month timeframe fits within the typical GBS progression window, though it's at the longer end of the spectrum.

Key Supporting Features for GBS:

  • Progressive bilateral ascending weakness beginning in legs and spreading to arms 1
  • Absent or decreased reflexes (absent plantar responses suggest areflexia) 1
  • Mild sensory involvement with predominantly motor symptoms 1
  • Normal spinal and brain MRI excluding CNS pathology 1
  • Timeframe: Most GBS patients reach maximum disability within 2 weeks, though progression up to 4 weeks is acceptable; beyond 4 weeks should raise concern for alternatives 1

Critical caveat: This patient's 1.5-month progression is slightly prolonged for typical GBS, which warrants consideration of chronic inflammatory demyelinating polyneuropathy (CIDP) if symptoms continue beyond 8 weeks 2.

GBS Subtypes to Consider:

  • AMAN (Acute Motor Axonal Neuropathy): Pure motor variant without sensory signs, can have normal or even exaggerated reflexes 1
  • AMSAN (Acute Motor Sensory Axonal Neuropathy): Both motor and sensory involvement 3

Important pitfall: Early electrodiagnostic studies may be completely normal in GBS, particularly in the first week or with proximal involvement 3. Normal nerve conduction studies do NOT exclude GBS, and repeat testing at 2-3 weeks is recommended 1.

Critical Differential Diagnoses to Exclude

1. Tuberculosis-Related Complications

Given the recent pulmonary TB diagnosis, several TB-related neurological complications must be excluded:

Tuberculous Radiculomyelitis/Myelitis:

  • TB can cause spinal cord involvement with ascending weakness 4
  • However, normal spinal MRI makes this less likely but does not completely exclude it
  • CSF analysis showing elevated protein with pleocytosis (>10-50 cells/μl) would favor infectious etiology over GBS 1

TB-associated GBS:

  • Mycobacterium tuberculosis has been suggested as a potential GBS trigger 1
  • The temporal association with TB diagnosis is noteworthy

2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

CIDP becomes the primary consideration if progression continues beyond 8 weeks 2:

  • Progressive bilateral leg and arm weakness over weeks to months
  • Sensory loss with areflexia
  • Elevated CSF protein without pleocytosis
  • Key distinguishing feature: CIDP progresses over >8 weeks, whereas GBS reaches nadir within 4 weeks 1, 2

3. Spinal Cord Pathology (Despite Normal MRI)

Anterior spinal artery infarction:

  • Can present with ascending weakness and sensory loss 5
  • Critical pitfall: Early MRI may be normal; repeat imaging may show cord edema or myelomalacia 5
  • Hyperreflexia and extensor plantar responses would favor this, but their absence doesn't exclude it early on

Atypical progressive myelopathy:

  • Can present with ascending weakness and initially normal or minimal MRI findings 6
  • Progressive spinal cord atrophy develops over time 6

4. Metabolic/Toxic Neuropathies

Acute intermittent porphyria (AIP):

  • Subacute motor-predominant neuropathy with autonomic features 7
  • Associated with abdominal pain, neuropsychiatric symptoms
  • Diagnosed by elevated urinary porphobilinogen and aminolevulinic acid 7

TB medication toxicity:

  • Isoniazid can cause peripheral neuropathy
  • Typically length-dependent sensory > motor neuropathy, not ascending pattern

5. Nodopathies/Autoimmune Nodal Neuropathies

Para/nodopathies with antibodies to node of Ranvier proteins:

  • Can mimic CIDP or GBS 8
  • Important because they don't respond to standard IVIG/steroids 8
  • Require specific antibody testing (anti-neurofascin, anti-contactin-1)

Diagnostic Algorithm

Immediate workup required:

  1. Lumbar puncture: Look for albuminocytologic dissociation (elevated protein, normal cell count) supporting GBS 1

    • If pleocytosis >50 cells/μl: Consider infectious radiculitis, including TB 1
  2. Nerve conduction studies and EMG:

    • May be normal early; repeat in 2-3 weeks if initially normal 1, 3
    • Look for sensorimotor polyradiculoneuropathy pattern 1
    • "Sural sparing pattern" supports GBS 1
  3. Serum antibody testing:

    • Anti-ganglioside antibodies (GD1b, GM1, GQ1b) for GBS 3
    • Anti-nodal antibodies if available 8
  4. Repeat spinal MRI if initial normal:

    • Cord edema or enhancement may appear later 5
    • Look for longitudinally extensive lesions 4
  5. Exclude metabolic causes:

    • Urinary porphobilinogen if abdominal pain or autonomic features present 7
    • Vitamin B12, folate, HIV testing
  6. TB-specific workup:

    • CSF analysis for TB (AFB, GeneXpert, culture) if pleocytosis present
    • Review TB medication history and timing

Management Implications

If GBS is confirmed (most likely based on presentation):

  • Immediate treatment with IVIG (0.4 g/kg daily for 5 days) or plasma exchange (200-250 ml/kg for 5 sessions) 1
  • Monitor respiratory function closely; 20% require mechanical ventilation 1
  • ICU admission if respiratory compromise, dysautonomia, or bulbar involvement 1

The 1.5-month progression timeframe is concerning and requires close monitoring for:

  • Treatment-related fluctuations (TRFs) if initially improves then worsens 1
  • Evolution to CIDP if progression continues beyond 8 weeks 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.